Iovance Biotherapeutics reported early pilot trial results for lifileucel in aggressive soft tissue sarcomas. The company plans to start a registrational trial and seek expedited FDA approval based on ...

Results presented here showed negative pressure wound therapy is a safe adjunct for soft tissue sarcoma treated with ...

Although relatively rare, soft tissue sarcoma after breast cancer treatment was linked most strongly to treatment with radiation, according to data from two large U.S. cohorts of breast cancer ...

Immunotherapy, particularly ICIs, shows potential in treating certain STS subtypes, but efficacy varies and requires further investigation. Blood-based biomarkers, including neutrophil-to-lymphocyte ...

Against the backdrop of a case report, pembrolizumab was investigated as immunotherapy for undifferentiated pleomorphic soft tissue sarcoma. Noting that immunotherapy for soft tissue sarcoma (STS) has ...

Soft tissue sarcomas (STSs) represent a diverse group of tumors that pose significant diagnostic and therapeutic challenges. In a recent review published in the journal Meta-Radiology, a team of ...

Synovial sarcoma, a rare cancer, thrives on glutamine. Blocking its nutrient supply with the drug V9302 stops tumor growth, offering a new way to treat the disease.

Efti in combination with pembrolizumab and radiotherapy demonstrates significant efficacy in the neoadjuvant setting in patients with soft tissue sarcoma Over three-fold increase in tumour ...

Iovance Biotherapeutics Inc. IOVA stock is trading higher on Friday, with no news to justify the movement. Investors should ...

Iovance Biotherapeutics reported early clinical trial data for lifileucel in advanced soft tissue sarcomas, showing promising efficacy signals. The company also received FDA Fast Track designation for ...

Angiosarcoma is an aggressive malignancy derived from endothelial cells, characterised by its rapid progression, heterogeneity and distinct clinical challenges. As a subset of soft tissue sarcomas, ...